Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-848d4c4894-x5gtn Total loading time: 0 Render date: 2024-05-15T04:12:48.866Z Has data issue: false hasContentIssue false

Chapter 27 - Cardiovascular system in endocrine disease

from Section III - Anatomical endocrine pathology

Published online by Cambridge University Press:  13 April 2017

By
Pooja Singhal  and
Jagdish Butany
Edited by
Ozgur Mete  and
Sylvia L. Asa
Ozgur Mete
Affiliation:
University of Toronto
Sylvia L. Asa
Affiliation:
University of Toronto
Get access
Type
Chapter
Information
Endocrine Pathology , pp. 959 - 978
Publisher: Cambridge University Press
Print publication year: 2000

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Schoen, F.J., Mitchell, R.N.. The heart. In Kumar, V., Abbas, A.K., Fausto, N., Aster, J.C., eds. Robbins and Cotran Pathologic Basis of Disease, 8th edn. Philadelphia PA: Elsevier-Saunders, 2010:529–588.Google Scholar
Du Bose, T.J., Miller, M.M., Moutos, D.M.. Embryonic heart rates compared in assisted and non-assisted pregnancies. ObGyn.net 2000 (http://www.obgyn.net/us/cotm/0001/ehr2000.htm, accessed 23 September 2015).Google Scholar
Cunningham, K.S., Veinot, V.P., Butany, J.. An approach to endomyocardial biopsy interpretation. J Clin Pathol 2006;59:121–129.Google Scholar
Severs, N.J. The cardiac gap junction and intercalated disc. Int J Cardiol 1990;26:137.Google Scholar
Veinot, J.P., Ghadially, F.N., Walley, V.M.. Light microscopy and ultrastructure of the blood vessels and heart. In Silver, M.D., Gotlieb, A.I., Schoen, F.J., eds. Cardiovascular Pathology, 3rd edn. New York: Churchill Livingstone, 2001:30–53.Google Scholar
Cooke, R.. The mechanism of muscle contraction. CRC Crit Rev Biochem 1986;21:53–118.Google Scholar
Katz, A.M.. Cardiomyopathy of overload: A major determinant of prognosis in congestive heart failure. N Eng J Med 1990;322:100–110.Google Scholar
Parker, T.G., Packer, S.E., Schneider, M.D.. Peptide growth factors can provoke "fetal" contractile protein gene expression in rat cardiac myocytes. J Clin Invest 1990;85:507–514.Google Scholar
Mercardier, J.J., Lompre, A.M., Duc, P., et al. Altered sarcoplasmic reticulum Ca2+-ATPase gene expression in the human ventricle during end-stage heart failure. J Clin Invest 1990;85:305–309.Google Scholar
Saito, Y., Nakao, K., Arai, H., et al. Augmented expression of atrial natriuretic polypeptide gene in ventricle of human failing heart. J Clin Invest 1989;83:298–305.CrossRefGoogle ScholarPubMed
Schneider, H.J., Aimaretti, G., Kreitschmann, I., et al. Hypopituitarism. Lancet 2007;369:1461–1470.Google Scholar
Prabhakar, V.K., Shalet, S.M.. Aetiology, diagnosis, and management of hypopituitarism in adult life. Postgrad Med J 2006;82:259–266.Google Scholar
Eden, S., Wiklund, O., Oscarsson, J., et al. Growth hormone treatment of growth hormone deficient adults results in a marked increase in Lp (a) and HDL cholesterol concentrations. Arterioscler Thromb Vasc Biol 1993;13:296.Google Scholar
Fazio, S., Sabatini, D., Capaldo, B., et al. A preliminary study of growth hormone in the treatment of dilated cardiomyopathy. N Eng J Med 1996;334:809.Google Scholar
Colao, A., Marullo, P., Di Somma, C., et al. Growth hormone and the heart. Clin Endocrinol (Oxf) 2001;54:137–154.CrossRefGoogle ScholarPubMed
Melmed, S.. Medical progress: acromegaly. N Engl J Med 2006;355:2558–2573.Google Scholar
Palmeiro, C.R., Anand, R., Dardi, I.K., et al. Growth hormone and the cardiovascular system. Cardiol Rev 2012;20:197–207.Google Scholar
Lombardi, G., Galdiero, M., Auriemma, R.S., et al. Acromegaly and the cardiovascular system. Neuroendocrinology 2006;83:211–217.Google Scholar
Pollack, A.. The heart in acromegaly. Clin Correlations 2010 (http://www.clinicalcorrelations.org/?p=3093, accessed 27 September 2015).Google Scholar
Kahaly, G., Olsharusen, K.V., Mohr-Kahaly, S., et al. Arrhythmia profile in acromegaly. Eur Heart J 1992;13:51–56.CrossRefGoogle ScholarPubMed
Vitale, G., Pivonello, R., Lombardi, G., et al. Cardiac abnormalities in acromegaly: pathophysiology and implications for management. Treat Endocrinol 2004;3:309–318.Google Scholar
Colao, A., Ferone, D., Marzullo, P., et al. Systemic complications of acromegaly: epidemiology, pathogenesis, and management. Endocr Rev 2004;25:102–152.Google Scholar
Ezzat, S., Serri, O., Chik, C., et al. Canadian consensus guidelines for the diagnosis and management of acromegaly. Clin Invest Med 2006;29:29–39.Google Scholar
Hunter, J.J., Chien, K.R.. Signaling pathways for cardiac hypertrophy and failure. N Engl J Med 1999;341:1276–1283.Google Scholar
Lie, J.T., Grossman, S.J.. Pathology of the heart in acromegaly: anatomic findings in 27 autopsied patients. Am Heart J 1980;100:41–52.Google Scholar
Sebastien, J.C., Neggers, C., van der Lely, A.. Somatostatin analog and pegvisomant combination therapy for acromegaly. Nat Rev Endocrinol 2009;5:546–552.Google Scholar
Bianco, A.C., Salvatore, D., Gereben, B., et al. Biochemistry, cellular and molecular biology, and physiological roles of the iodothyronine selenodeiodinases. Endocrine Rev 2002;23:38–89.Google Scholar
Everts, M.E., Verhoeven, F.A., Bezstarosti, K., et al. Uptake of thyroid hormones in neonatal rat cardiac myocytes. Endocrinology 1996;137:4235–4242.Google Scholar
Morkin, E.. Regulation of myosin heavy chain genes in the heart. Circulation 1993;87:1451–1460.CrossRefGoogle ScholarPubMed
Ojamaa, K., Klemperer, J.D., Mac Gilbray, S.S., et al. Thyroid hormone and hemodynamic regulation of beta-myosin chain promotor in the heart. Endocrinology 1996;137:802–808.CrossRefGoogle Scholar
Dillmann, W.H.. Cellular action of thyroid hormone on the heart. Thyroid 2002;12:447–452.Google Scholar
Klein, I., Ojamaa, K.. Thyroid hormone and the cardiovascular system. N Engl J Med 2001;344:501–509.Google Scholar
Ojamaa, K., Sabet, A., Kenessey, A., et al. Regulation of rat cardiac Kv1.5 gene expression by thyroid hormone is rabid and chamber specific. Endocrinology 1999;140:3170–3176.Google Scholar
Hiroi, Y., Kim, H.H., Ying, H., et al. Rapid nongenomic actions of thyroid hormone. Proc Natl Acad Sci USA 2006;103:14104–14109.Google Scholar
Kuzman, J.A., Gerdes, A.M., Kobayashi, S., et al. Thyroid hormone activates Akt and prevents serum starvation-induced cell death in neonatal rat cardiomyocytes. J Mol Cell Cardiol 2005;39:841–844.Google Scholar
Klein, I., Danzi, S.. Thyroid disease and the heart. Circulation 2007;116:1725–1735.Google Scholar
Danzi, S., Klein, I.. Thyroid hormone and the cardiovascular system. Minerva Endocrinologica 2004;29:139–150.Google Scholar
Taddei, S., Caraccio, N., Virdis, A., et al. Impaired endothelium-dependent vasodilatation in subclinical hypothyroidism: beneficial effect of levothyroxine therapy. J Clin Endocrinol Metab 2003;88:3731–3737.Google Scholar
Marvisi, M., Zambrelli, P., Brianti, M., et al. Pulmonary hypertension is frequent in hyperthyroidism and normalizes after therapy. Eur J Intern Med 2006;17:267–271.Google Scholar
Duntas, L.H.. Thyroid disease and lipids. Thyroid 2002;12:287–293.Google Scholar
Caraccio, N., Ferrannini, E., Monzani, F.. Lipoprotein profile in subclinical hypothyroidism: response to replacement, a randomized placebo-controlled study. J Clin Endocrinol Metab 2002;87:1533–1538.Google Scholar
Rush, J., Danzi, S., Klein, I.. Role of thyroid disease in the development of statin-induced myopathy. Endocrinologist 2006;145:574–581.Google Scholar
Zonszein, J., Fein, F.S., Sonnenblick, E.H.. The heart and endocrine disease. In Schlant, R.C., Alexander, R.W., eds. Hurst’s: The Heart, Arteries and Veins, Vol. 8. 1994:1907–1985.Google Scholar
Devereux, R.B., Kramer-Fox, R., Kligfield, P.: Mitral valve prolapse: causes, clinical manifestations and, management. Ann Intern Med 1989;111:305–317.Google Scholar
Maitra, A.. The endocrine system. In Kumar, V., Abbas, A.K., Fausto, N., Aster, J.C., eds. Robbins and Cotran Pathologic Basis of Disease, 8th edn. Philadelphia PA: Elsevier-Saunders, 2010:1097–1164.Google Scholar
Jajiri, J., Morita, M., Higashi, K, et al. The cause of low voltage QRS complex in primary hypothyroidism. Pericardial effusion or thyroid hormone deficiency? Jpn Heart J 1985;26:539–547.Google Scholar
Schenck, J.B., Rizvi, A.A., Lin, T.. Severe Primary Hypothyroidism manifesting with torsade de pointes. Am J Med Sci 2006;331:154–156.Google Scholar
Jameson, J.L., Weetman, A.P.. Disorders of the thyroid gland. In Kaspar, D.L., Braunwald, E., Fauci, A.S., et al. eds. Harrison’s Principles of Internal Medicine: Vol II. Toronto: McGraw Hill, 2005:2104–2127.Google Scholar
Kelly, J.K., Butt, J.C.. Fatal myxedema pericarditis in a Christian scientist. Am J Clin Pathol 1986;86:113.Google Scholar
Santos, A.D., Miller, R.P., Puthenpurakal, K.M., et al. Echocardiographic characterization of the reversible cardiomyopathy of hypothyroidism. Am J Med 1980;68:675.Google Scholar
Klein, I., Becker, D.V., Levey, G.S.. Treatment of hyperthyroid disease. Ann Intern Med 2008;121:281–288.Google Scholar
Nakazawa, H.K., Sakuri, K., Hamada, N., et al. Management of atrial fibrillation in the post-thyrotoxic state. Am J Med 1982;72:903–906.Google Scholar
Roti, E., Montermini, M., Roti, S., et al. The effect of diltiazem, a calcium channel-blocking drug, on cardiac rate and rhythm in hyperthyroid patients. Arch Intern Med 1998;148:1919–1921.Google Scholar
Danzi, K., Klein, I.. Thyroid hormone and blood pressure regulation. Curr Hypertens Rep 2003;5:513–520.Google Scholar
Marx, S.J.. Hyperparathyroid and Hypoparathyroid disorders. N Engl J Med 2000;343:1863–1875.Google Scholar
Farford, B., Presutti, J., Moraghan, T.J.. Nonsurgical management of primary hyperparathyroidism. Mayo Clin Proc 2007;82:351–355.Google Scholar
Potts, J.T.. Disease of the parathyroid gland and other hyper- and hypocalcemic disorders. In Kaspar, D.L., Braunwald, E., Fauci, A.S., et al. eds. Harrison’s Principles of Internal Medicine. Toronto: McGraw Hill, 2005:2249–2268.Google Scholar
Hedback, G., Tisell, L.E., Bengtsson, B.A., et al. Premature death in patients operated on for primary hyperparathyroidism. World J Surg 1990;14:829–836.Google Scholar
Fliser, D., Franek, E., Fode, P., et al. Subacute infusion of physiological doses of parathyroid hormones raises blood pressure in humans. Nephrol Dial Transplant 1997;12:933–938.Google Scholar
Andersson, P., Rydberg, E., Willenheimer, R.. Primary hyperparathyroidism and heart disease-a review. Eur Heart J 2004;25:1776–1787.Google Scholar
Gennari, C., Nami, R., Gonnelli, S.. Hypertension and primary hyperparathyroidism: the role of adrenergic and renin–angiotensin-aldosterone systems. Miner Electrolyte Metab 1995;21:77–81.Google Scholar
Schluter, K.D., Weber, M., Piper, H.M.. Parathyroid hormone induces protein kinase C but not adenylate cyclase in adult cardiomyocytes and regulates cyclic AMP levels via protein kinase C-dependent phosphodiesterase activity. Biochem J 1995;310:439–444.CrossRefGoogle Scholar
Shimoyama, M., Ogino, K., Furuse, Y., et al. Signaling pathway and chronotropic action of parathyroid hormone in isolated perfused rat heart. J Cardiovasc Pharmacol 2001;38:491–499.Google Scholar
Hurley, K., Baggs, D.. Hypocalcemic cardiac failure in the emergency department. J Emerg Med 2005;28:155–159.Google Scholar
Stefenelli, T., Mayr, H., Bergler-Klein, J., et al. Primary hyperparathyroidism: incidence of cardiac abnormalities and partial reversibility after successful parathyroidectomy. Am J Med 1993;95:197–202.Google Scholar
Stefenelli, T., Abela, C., Frank, H., et al. Cardiac abnormalities in patients with primary hyperparathyroidism: implications for follow-up. J Clin Endocrinol Metab 1997;82:106–112.Google Scholar
Fitzpatrick, L.A., Bilezikian, J.P., Silverberg, S.J.. Parathyroid hormone and the cardiovascular system. Curr Osteoporos Rep. 2008;6:77–83.Google Scholar
Lester, W.M., Gotlieb, A.I.. Cardiovascular effects of systemic diseases and conditions. In Silver, M.D., Gotlieb, A.I., Schoen, F.J., eds. Cardiovascular Pathology, 3rd edn. New York: Churchill Livingstone, 2001:493–540.Google Scholar
Bilezikian, J.P., Potts, J.T. Jr., Guleihan Gel, H., et al. Summary statement from a workshop on asymptomatic primary hyperparathyroidism: a perspective for the 21st century. J Bone Miner Res 2002;17:N2–N11.Google Scholar
Williams, G.H., Dluhy, R.G.. Disorders of the adrenal cortex. In Kaspar, D.L., Braunwald, E., Fauci, A.S., et al. eds. Harrison’s Principles of Internal Medicine. Toronto: McGraw Hill, 2005:2127–2148.Google Scholar
Connell, J.M., Whitworth, J.A., Davies, D.L., et al. Effects of ACTH and cortisol administration on blood pressure, electrolyte metabolism, atrial natriuretic peptide and renal function in normal man. J Hypertens 1987;5:425–433.Google Scholar
Fimognari, F.L., Piccirillo, G., Lama, J., et al. Associated daily biosynthesis of cortisol and thromboxane A2: a preliminary report. J Lab Clin Med 1996;128:115–121.Google Scholar
Kirilov, G., Tomova, A., Dakovska, L., et al. Elevated plasma endothelin as an additional cardiovascular risk factor in patients with Cushing’s syndrome. Eur J Endocrinol 2003;149:549–553.Google Scholar
Kelly, J.J., Martin, A., Whitworth, J.A.. Role of erythropoietin in cortisol-induced hypertension. J Hum Hypertens 2000;14:195–198.CrossRefGoogle ScholarPubMed
Langenfeld, M.R., Veelken, R., Schobel, H.P., et al. Is endogenous erythropoietin a pathogenetic factor in the development of essential hypertension? Nephrol Dial Transplant 1997;12:1155–1160.CrossRefGoogle ScholarPubMed
Whitworth, J.A., Mangos, G.J., Kelly, J.J.. Cushing, cortisol, and cardiovascular disease. Hypertension 2000;36:912–916.Google Scholar
Williamson, P.M., Kelly, J.J., Whitworth, J.A.. Dose–response relationships and mineralocorticoid activity in cortisol-induced hypertension in humans. J Hyertens 1996;14:S37–S41.Google Scholar
Arnaldi, G., Angeli, A., Atkinson, A.B., et al. Diagnosis and complications of Cushing’s syndrome: a consensus statement. J Clin Endocrinol Metab 2003;88:5593–5602.Google Scholar
De Leo, M., Pivonello, R., Auriemma, R.S., et al. Cardiovascular disease in Cushing’s syndrome: heart versus vasculature. Neuroendocrinology 2010;92:50–54.Google Scholar
Sugihara, N., Shimizu, M., Ino, H., et al. Cardiac characteristics and postoperative courses in Cushing’s syndrome. Am J Cardiol 1992;69:1475–1480.Google Scholar
Oelkers, W.. Adrenal insufficiency. N Engl J Med 1996;335:1206–1212.Google Scholar
Hartog, M., Joplin, G.F.. Effects of cortisol deficiency on the electrocardiogram. Br Med J 1968;2:275–277.Google Scholar
Findling, J.W., Raff, H.. Newer diagnostic techniques and problems in Cushing’s disease. Endocinol Metab Clin North Am 1999;28:191–210.Google Scholar
Invitti, C., Giraldi, F.P., De Martin, M., et al. Diagnosis and management of Cushing’s syndrome: results of an Italian multicentre study. J Clin Endocrinol Metab 1999;84:440–448.Google Scholar
Galetta, F., Franzoni, F., Bernini, G., et al. Cardiovascular complications in patients with pheochromocytoma: a mini-review. Biomed Pharmacother 2010;64:505–509.CrossRefGoogle ScholarPubMed
Hall, W.D., Wollam, G.L., Tuttle, E.P. Jr. Diagnostic evaluation of the patient with systemic arterial hypertension. In Schlant, R.C., Alexander, R.W., eds. Hurst’s: The Heart, Arteries and Veins, Vol. 8. 1994:1403–1426.Google Scholar
Shaw, J.E., Sicree, R.A., Zimmet, P.Z.. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Practice 2010;87:4–14.Google Scholar
Powers, A.C.. Diabetes mellitus. In Kaspar, D.L., Braunwald, E., Fauci, A.S., et al. eds. Harrison’s Principles of Internal Medicine. Toronto: McGraw Hill, 2005:2152–2185.Google Scholar
Jellinger, P.S.. Metabolic consequences of hyperglycemia and insulin resistance. Clinical Cornerstone 2007;8:s30–s42.Google Scholar
Muniyappa, R., Montagnani, M., Koh, K.K., et al. Cardiovascular actions of insulin. Endocr Rev 2007;28:473–491.Google Scholar
Kahn, N.N., Bauman, W.A., Hatcher, V.B., et al. Inhibition of platelet aggregation and the stimulation of prostacyclin synthesis by insulin in humans. Am J Physiol 1993;265:H2160–H2167.Google Scholar
Vincent, M.A., Dawson, D., Clark, A.D.H., et al. Skeletal muscle microvascular recruitment by physiological hyperinsulinemia precedes increases in total blood flow. Diabetes 2002;51:42–48.CrossRefGoogle ScholarPubMed
Kahn, A.M., Seidel, C.L., Allen, J.C., et al. Insulin reduces contraction and intracellular calcium concentration in vascular smooth muscles. J Clin Invest 1993;92:1161–1167.Google Scholar
von Lewinski, D., Bruns, S., Walther, S., et al. Insulin causes Ca2+ dependent and Ca2+-independent positive inotropic effects in failing human myocardium. Circulation 2005;111:2588–2595.Google Scholar
Maier, S., Aulbach, F., Simm, A., et al. Stimulation of L-type Ca2+ current in human atrial myocytes by insulin. Cardiovasc Res 1999;44:390–397.Google Scholar
Sundell, J., Knuuti, J.. Insulin and myocardial blood flow. Cardiovasc Res 2003;57:312–319.Google Scholar
Ayramoglu, R.K., Basciano, H., Adeli, K.. Lipid and lipoprotein dysregulation in insulin resistant states. Clin ChimiActa 2006;368:1–19.Google Scholar
Boden, G., Laakso, M.. Lipids and glucose in type 2 diabetes: what is the cause and effect? Diabetes Care 2008;27:2253–2259.Google Scholar
Dokken, B.B.. The pathophysiology of cardiovascular disease and diabetes: Beyond blood pressure and lipids. Diabetes Spectrum 2008;21:160–165.CrossRefGoogle Scholar
Atkinson, M.A., Eisenbarth, G.S.. Type 1 diabetes: new perspectives on disease pathogenesis and treatment. Lancet 2001;358:221–229.CrossRefGoogle ScholarPubMed
Canadian Diabetes Association Clinical Practice Guidelines Expert Committee. Clinical practice guidelines for the prevention and management of diabetes in Canada. Can J Diabetes 2008;32:s10.Google Scholar
Asbun, J., Villarreal, F.J.. The pathogenesis of myocardial fibrosis in the setting of diabetic cardiomyopathy. JACC 2006;47:693–700.Google Scholar
Goldberg, R.B., Meliies, M.J., Sacks, F.M., et al. Cardiovascular events and their reduction with pravastatin in diabetic and glucose intolerant myocardial infarction survives with average cholesterol levels: subgroup analysis in the cholesterol and recurrent events (CARE) trial. Circulation 1998;98:2513–2519.Google Scholar
Pyorala, K., Pedersen, T.R., Kjekshus, J., et al. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease: a subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care 1997;20:614–620.Google Scholar
MRC/BHF Heart Production. Study of cholesterol lowering with simvastatin in 20 536 high-risk patients: a randomized placebo controlled trial. Lancet 2002;36:7–22.Google Scholar
Antiplatelet Trialists’ Collaboration. Secondary prevention of vascular disease by prolonged antiplatelet treatment. Br Med J (Clin Res Ed) 1998;296:320–331.Google Scholar
CAPRIE Steering Committee. A randomized, blinded, trial of clopidogrel versus aspirin in patients at risk of ischemic events (CAPRIE). Lancet 1996;348:1329–1339.Google Scholar
Bhattacharyya, S., Davar, J., Dreyfus, G., et al. Carcinoid heart disease. Circulation 2007;116:2860–2865.Google Scholar
Lundin, L., Norheim, I., Landelius, J., et al. Carcinoid heart disease: relationship of circulating vasoactive substance to ultrasound-detectable cardiac abnormalities. Circulation 1988;77:264–269.Google Scholar
Gustafsson, B.I., Hauso, O., Drozdov, I., et al. Carcinoid heart disease. Int J Cardiol 2008;129:318–324.Google Scholar
Waltenberger, J., Lundin, L., Oberg, K., et al. Involvement of transforming growth factor in the formation of fibrotic lesions in carcinoid heart disease. Am J Pathol 1993;142:71–78.Google Scholar
Connolly, H., Crary, J., McGoon, M., et al. Valvular heart disease associated with fenfluramine–phentermine. N Engl J Med 1997;337:581–588.Google Scholar
Ghevariya, V., Malieckal, A., Ghevariya, N., et al. Carcinoid tumors of the gastrointestinal tract. South Med J 2009;102:1032–1040.CrossRefGoogle ScholarPubMed
Janson, E.T., Holmberg, L., Stridberg, M., et al. Carcinoid tumors: analysis of prognostic factors and survival in 301 patients from a referral center. Ann Oncol 1997;8:685–690.Google Scholar
Krenning, E.P., Kooij, P.P., Bakker, W.H., et al. Radiotherapy with a radiolabeled somatostatin analogue [111-In-DTPA-d-Phe1]-octreotide. A case history. Ann N Y Acad Sci 1994;733:496–506.Google Scholar
Modlin, I.M., Kidd, M., Latich, I., et al. Current status of gastrointestinal carcinoids. Gastroenterology 2005;128:1717–1751.Google Scholar
Mansencal, N., Mitry, E., Forissier, J., et al. Assessment of patent foramen ovale in carcinoid heart disease. Am Heart J 2006;151:e1–e6.Google Scholar
Wilkes, D., Charitakis, K., Basson, C.T.. Inherited disposition to cardiac myxoma development. Nat Rev Cancer 2006;6:157–165.Google Scholar
Stratakis, C.A., Kirschner, L.S., Carney, J.A.. Carney complex: diagnosis and management of the complex of spotty skin pigmentation, myxomas, endocrine overactivity, and schwannomas. Am J Med Genet 1998;80:183–185.Google Scholar
Stergiopoulos, S.G., Stratakis, C.A.. Human tumors associated with Carney complex and germline PRKAR1A mutations: a protein kinase A disease! FEBS Lett 2003;546:59–64.Google Scholar
Stratakis, C.A., Kirschner, L.S., Carney, J.A.. Clinical and molecular features of the Carney complex: diagnostic criteria and recommendations for patient evaluation. J Clin Endocrinol Metab 2001;86:4041–4046.Google Scholar
Bossis, I., Voutetakis, A., Bei, T., et al. Protein kinase A and its role in human neoplasia: the Carney complex paradigm. Endocr Relat Cancer 2004;11:265–280.Google Scholar
Stratakis, C.A., Courcoutsakis, N.A., Abati, A., et al. Thyroid gland abnormalities in patients with the syndrome of spotty skin pigmentation, myxomas, endocrine overactivity, and schwannomas (Carney complex). J Clin Endocrinol Metab 1997;82:2037–2043.Google Scholar

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×